CURRENT
ISSUE
1572
The FDA has approved Inbrija (Acorda), an orally inhaled dry-powder formulation of levodopa, for intermittent treatment of "off" episodes in patients with Parkinson's disease (PD) being treated with carbidopa/levodopa (Sinemet, and others)....  Continue reading
More from Issue 1572
Previous Issue: 1571      May 6, 2019
Coming Soon
Drugs for Psoriasis
Romosozumab (Evenity) for Postmenopausal Osteoporosis
Prucalopride (Motegrity) for Chronic Idiopathic Constipation
Risankizumab (Skyrizi) for Psoriasis
Tafenoquine (Arakoda and Krintafel) for Malaria
Search
Subscribe
Conversation
Follow us  facebook        Email Alerts
 Tweets
FROM
ISSUE
1572
The FDA has approved omadacycline (Nuzyra – Paratek), a semisynthetic tetracycline derivative, for once-daily IV and oral treatment of community-acquired bacterial pneumonia (CAP) and acute bacterial skin and skin structure infections (ABSSSIs) in adults. ... Continue reading